Normal view MARC view ISBD view

A simulation study on downstream processing of monoclonal antibodies production using superpro designer / Muhamad Nur Iman Bin Ahmad Razali

By:

Muhamad Nur Iman Ahmad Razali

Material type: Text

TextPublication details: Kuantan, Pahang : UMP, 2009Description: xiv, 53 p. : ill. (some col.) ; 30 cm. + 1 computer discISBN:

THE0002288(Local)

Other title:

A simulation study on downstream processing of monoclonal antibodies production using superpro designer [computer file]

Subject(s):

Monoclonal antibodies

Dissertation note: Project paper (Bachelor of Chemical Engineering (Biotechnology)) -- Universiti Malaysia Pahang - 2009 Abstract: The production of monoclonal antibodies and Fc fusion proteins form the largest and most rapidly expanding category of the biopharmaceuticals today with the annual sales exceeding USD$8 billion with the application across a wide range of diseases especially for the immunotherapy purpose. With the growth of this class of biomolecules, significant thought on the most efficient downstream processing steps for monoclonal antibodies has been taken into the highly consideration by the manufacturer in order to obtain the highest yield with the highest purity of the product which is why the simulation study are crucial in this development. The objectives of this study are to propose the most suitable framework of downstream processing for monoclonal antibodies production in order to achieve highest purities of mAbs and to stimulate the propose framework using SuperPro Designer® simulator. The process was initially done via the disk stack centrifuge and followed by microfiltration in order to harvest the protein. Three column of chromatography (Protein A affinity, anion exchange and hydrophobic interaction) were used to obtain the highest purity of the therapeutic. Viral inactivation also was employed to free the product from the endotoxins and pyrogens. The propose steps then, was introduced into the SuperPro Designer® simulator and the result obtained were 100% purity of IgG with 9.49345 g/L of concentration and 0.16687 kg/batch with 76.3% of recovery of the product.

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings ( 2 )
Title notes ( 3 )

Holdings
Item type	Current library	Call number	Copy number	Status	Date due	Barcode
Final Year Report	UMPLIB GAMBANG	QR186.85 .I43 2009 rs Bc. (Browse shelf(Opens below))	1	Not for loan		0000042957
Final Year Report	UMPLIB GAMBANG	CD 4010 \| QR186.85 .I43 2009 rs Bc. (Browse shelf(Opens below))	1	Not for loan		0000042958

Project paper (Bachelor of Chemical Engineering (Biotechnology)) -- Universiti Malaysia Pahang - 2009

Bibliography : p. 51-52

The production of monoclonal antibodies and Fc fusion proteins form the largest and most rapidly expanding category of the biopharmaceuticals today with the annual sales exceeding USD$8 billion with the application across a wide range of diseases especially for the immunotherapy purpose. With the growth of this class of biomolecules, significant thought on the most efficient downstream processing steps for monoclonal antibodies has been taken into the highly consideration by the manufacturer in order to obtain the highest yield with the highest purity of the product which is why the simulation study are crucial in this development. The objectives of this study are to propose the most suitable framework of downstream processing for monoclonal antibodies production in order to achieve highest purities of mAbs and to stimulate the propose framework using SuperPro Designer® simulator. The process was initially done via the disk stack centrifuge and followed by microfiltration in order to harvest the protein. Three column of chromatography (Protein A affinity, anion exchange and hydrophobic interaction) were used to obtain the highest purity of the therapeutic. Viral inactivation also was employed to free the product from the endotoxins and pyrogens. The propose steps then, was introduced into the SuperPro Designer® simulator and the result obtained were 100% purity of IgG with 9.49345 g/L of concentration and 0.16687 kg/batch with 76.3% of recovery of the product.